Information from the UPC Registry

No items found.

December 1, 2022

Download PDF

Table of contents

Toc Heading
Toc Heading

No items found.

The Registry of the Unified Patent Court maintains a number of Registers which are publicly accessible via their website at www.unified-patent-court.org.

Cases

Most obviously, there is a register of cases filed at the UPC. Cases appear there shortly after they are filed, once they have passed through the initial check by Registry staff (which may be before the case has been served on the defendant). Search is possible in various fields, including party and representative name, and proceeding type. The broadest way to search is to select a particular type of action, such as "infringement" or "revocation", which will return all the actions of that type. (A date range search will also return opt out requests and UPC representative registration requests, which are also a type of UPC proceeding, and so is not effective as a way to search the litigation cases generally). The information shown is currently a little incomplete. It is expected that this will improve in time.

Opt-outs of (non-unitary) European Patents

Then, there is a register of opt outs. Here, you enter a European patent number, and if it has been opted out then details of the opt out appear. If it has not been opted out, i.e. is subject to the jurisdiction of the UPC, then "No results found" is returned.

Representatives

Finally, there is a register of representatives. It is only possible to search by name of representative or by their entitlement to represent as set out in the person's application to be recorded as a representative. This will usually be as a lawyer authorised to practice in a UPC member state, or as a European patent attorney with one of a number of possible additional qualifications. Selecting one of those entitlements will return all representatives having that entitlement.

For all of these public facing Register search tools, there are also equivalent search interfaces available within the UPC Case Management System, available to registered users of the CMS. These provide greater detail and the information is more reliably presented. Therefore, please contact us if you are interested in a particular patent or litigation case.

The Latest Thought Leadership pieces in the Content Hub

See all articles

What is the Unified Patent Court?

November 1, 2022

The Unified Patent Court ("UPC") is a new pan-European court which opened for business on 1 June 2023. It adjudicates disputes relating to the new Unitary Patents and also to existing and future...

What is the Unitary Patent and how do I get one?

November 1, 2022

The Unitary Patent (UP) is a single patent right, obtained via the European Patent Office, covering all EU Member States which have ratified the agreement at the patent grant date, and is subject to...

Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Latest Insights

Showing 0 of 100

The UPC After Three Years: From Experiment to Enforcement Forum

15 July 2026

1,282 cases filed at the UPC in three years: infringement actions have surged while revocation filings stayed flat, easing fears the Court would become a European patent graveyard.

Choosing your SEP battleground: UPC, Germany or UK?

07 June 2026

Choosing the right venue for SEP litigation can significantly influence the outcome of FRAND disputes. This article compares the UPC, German and UK courts, examining their approaches to injunctions, FRAND defences, rate-setting and enforcement. It highlights the strategic advantages of each jurisdiction and explains why many SEP owners are increasingly turning to the UK and UPC as part of their European enforcement strategy.

Synthetic Lethality & AI: IP Strategy in Oncology

26 May 2026

This article explores the resurgence of synthetic lethality in precision oncology, highlighting how AI and machine learning are accelerating the discovery of new therapeutic targets. It also examines growing clinical activity, investment, and the evolving intellectual property challenges shaping this emerging field.

Inside the Visser AI Launch Party

20 May 2026

EIP has officially launched Visser AI®, our hybrid intelligence service for patent drafting and prosecution. Watch the launch film from our event at The Boundary in Shoreditch, and discover how our team of European and US patent attorneys — working with the Patently AI platform , delivers faster, lower-cost work at the EPO, USPTO and beyond.

Protecting Your Startup: Five Intellectual Property Mistakes to Avoid

20 May 2026

Early‑stage startups often focus on product development and fundraising, but overlooking intellectual property (IP) can seriously damage long‑term value. This article explores five common IP mistakes startups make, with a particular focus on patents. It covers the risks of filing patents without professional advice, making public disclosures too early, failing to put enforceable contracts in place with third parties, misunderstanding what patent rights actually provide, and neglecting to develop a clear IP strategy. By highlighting these pitfalls and offering practical guidance, the article helps startups protect their innovations, strengthen their commercial position, and improve their prospects with investors.

Technology, Patents, and Sport

13 May 2026

VAR, goal-line tech, AI 3D player avatars, wearable trackers, the technology reshaping the 2026 World Cup and elite sport rests on a patent system that makes the R&D investment behind it worth taking.

Patents or Trade Secrets? When to Patent in Deep Tech Innovation

11 May 2026

Deep tech companies face unique IP challenges due to long development cycles, high upfront investment, and complex technologies that combine products and processes. This article explores when patents, trade secrets, or a combination of both offer the strongest protection. It explains how factors such as detectability, reverse engineering risk, disclosure to third parties, and employee mobility should shape IP strategy decisions. While patents are often best suited to externally visible or licensable technologies, trade secrets can be highly effective for internal processes and know‑how that deliver performance or cost advantages.

Is Your AI Conversation Privileged?

08 May 2026

Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.

The evolution of nucleic acid sequencing and what it means for Genomics and IP

27 April 2026

This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.

World IP Day: The big ideas shaping IP's fastest-moving fields

24 April 2026

For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.

Meet the EIP team heading to INTA 2026 in London

23 April 2026

INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.

National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?

27 March 2026

National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.

Make your bio(pharma) IP investment ready

22 March 2026

This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.

Are professional guidelines making Patent Attorneys too cautious on AI?

19 February 2026

As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.

Beyond CRISPR: Precision to Platform

23 January 2026

Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.